Document:

Form of Medium-Term Notes, Series K, Securities Linked to a Global Basket

 Exhibit 4.1 

 
  

[Face of Note] 
 Unless this certificate is presented by an authorized representative of The Depository Trust Company, a New York corporation (“DTC”), to the Company or its agent for registration of
transfer, exchange or payment, and any certificate issued is registered in the name of Cede & Co. or in such other name as requested by an authorized representative of DTC (and any payment is made to Cede & Co. or such other entity
as is requested by an authorized representative of DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, Cede & Co., has an interest herein.

  

			
	CUSIP NO. 94986RQG9	 	FACE AMOUNT:
$                      
	REGISTERED NO.     	 	

  
 WELLS FARGO & COMPANY

 MEDIUM-TERM NOTE, SERIES K 
 Due Nine Months or More From Date of Issue 
 Securities Linked to a
Global Basket of Equity Indices and ETFs 
 due July 10, 2017 

 
  
 WELLS FARGO & COMPANY, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter called the “Company,” which term includes any successor
corporation under the Indenture hereinafter referred to), for value received, hereby promises to pay to CEDE & Co., or registered assigns, an amount equal to the Redemption Amount (as defined below), in such coin or currency of the United
States of America as at the time of payment is legal tender for payment of public and private debts, on the Stated Maturity Date. The “Initial Stated Maturity Date” shall be July 10, 2017. If no Market Disruption Event (as
defined below) occurs or is continuing with respect to a Basket Component (as defined below) on the scheduled Calculation Day (as defined below), the Initial Stated Maturity Date will be the “Stated Maturity Date.” If a Market
Disruption Event occurs or is continuing with respect to a Basket Component on the scheduled Calculation Day, the “Stated Maturity Date” shall be the later of (i) three Business Days (as defined below) after the postponed
Calculation Day with respect to such Basket Component (or, if the Calculation Day is postponed with respect to more than one Basket Component, three Business Days after the latest postponed Calculation Day) and (ii) the Initial Stated Maturity
Date. This Security shall not bear any interest. 
 Any payments on this Security at Maturity will be made
against presentation of this Security at the office or agency of the Company maintained for that purpose in the City of Minneapolis, Minnesota and at any other office or agency maintained by the Company for such purpose. 

 “Face Amount” shall mean, when used with respect to this
Security, the amount set forth on the face of this Security as its “Face Amount.” 
 Determination of Redemption Amount

 The “Redemption Amount” of this Security will equal: 

 

	 	•	 if the Ending Price is greater than the Starting Price: the Face Amount plus: 

 
  

																					
		 	  
	 	 Face Amount x  
	 	  
	 		 	 Ending Price – Starting Price

Starting Price
	 		 	  
	 	   x  Participation Rate  
	 	  
	 	 ;

  

	 	•	 if the Ending Price is less than or equal to the Starting Price, but greater than or equal to the Threshold Price: the Face Amount; or

  

	 	•	 if the Ending Price is less than the Threshold Price: the Face Amount minus: 

 
  

															
		 	  
	 	 Face Amount x  
	 	  
	 		 	 Threshold Price – Ending Price

Starting Price
	 		 	  

 “Basket” shall mean a basket comprised of the following Basket
Components, with the return of each Basket Component having the weighting noted parenthetically: S&P 500 Index (70%); iShares MSCI EAFE Index Fund (15%); S&P MidCap 400 Index (8%); iShares MSCI Emerging Markets Index Fund (4%); and Russell
2000 Index (3%). 
 “Index Components” shall mean the S&P 500 Index, the S&P MidCap 400
Index and the Russell 2000 Index. 
 “ETF Components” shall mean the iShares MSCI EAFE Index
Fund and the iShares MSCI Emerging Markets Index Fund. 
 “Basket Component” shall mean each of
the Index Components and the ETF Components. 
 “Underlying Index” shall mean the MSCI EAFE
Index in respect of the iShares MSCI EAFE Index Fund and the MSCI Emerging Markets Index in respect of the iShares MSCI Emerging Markets Index Fund. 
 The “Pricing Date” shall mean July 3, 2013. 

The “Starting Price” is 100. 

The “Ending Price” will be calculated based on the weighted returns of the Basket Components and will be
equal to the product of (i) 100 and (ii) an amount equal to 1 plus the sum of: (A) 70% of the Component Return of the S&P 500 Index; (B) 15% of the Component 

  
 2 

 
Return of the iShares MSCI EAFE Index Fund; (C) 8% of the Component Return of the S&P MidCap 400 Index; (D) 4% of the Component Return of the iShares MSCI Emerging Markets Index
Fund; and (E) 3% of the Component Return of the Russell 2000 Index. 
 The “Component
Return” of an Index Component will be equal to: 
 Final Component Level – Initial Component Level

 Initial Component Level 
 where, 
  

	 	•	 the “Initial Component Level” is the Closing Level of such Index Component on the Pricing Date; and 

 

	 	•	 the “Final Component Level” will be the Closing Level of such Index Component on the Calculation Day. 

 

	 	 	 The Initial Component Levels of the Index Components are as follows: S&P 500 Index (1615.41); S&P MidCap 400 Index (1171.34); and Russell
2000 Index (991.13). 

  

The “Closing Level” of an Index Component on any Trading Day means the official closing level of such
Index Component as reported by the Index Sponsor of such Index Component on such Trading Day. 
 The
“Component Return” of an ETF Component will be equal to: 
 Final Component Price – Initial Component
Price 
 Initial Component Price 
 where, 
  

	 	•	 the “Initial Component Price” is the Fund Closing Price of such ETF Component on the Pricing Date; and

  

	 	•	 the “Final Component Price” will be the Fund Closing Price of such ETF Component on the Calculation Day.

  

	 	 	 The Initial Component Prices of the ETF Components are as follows: iShares MSCI EAFE Index Fund ($57.57); and iShares MSCI Emerging Markets Index
Fund ($37.58). 

 The “Fund Closing Price,” with respect to an ETF Component
on any Trading Day, means the product of (i) the Closing Price of one share of such ETF Component (or one unit of any other security for which a Fund Closing Price must be determined) on such Trading Day and (ii) the Adjustment Factor
applicable to such ETF Component on such Trading Day. 

  
 3 

 The “Closing Price” with respect to a share of an ETF
Component (or one unit of any other security for which a Closing Price must be determined) on any Trading Day means the price, at the scheduled weekday closing time, without regard to after hours or any other trading outside the regular trading
session hours, of the share on the principal United States securities exchange registered under the Securities Exchange Act of 1934, as amended, on which the share (or any such other security) is listed or admitted to trading. 

The “Adjustment Factor” means, with respect to a share of an ETF Component (or one unit of any other
security for which a Fund Closing Price must be determined), 1.0, subject to adjustment in the event of certain events affecting the shares of such ETF Component. See “Anti-dilution Adjustments Relating To An ETF Component; Alternate
Calculation—Anti-dilution Adjustments” below. 
 The “Threshold Price” will be equal
to 85% of the Starting Price. 
 The “Participation Rate” is 113.50%. 

“Business Day” shall mean a day, other than a Saturday or Sunday, that is neither a legal holiday nor a
day on which banking institutions are authorized or required by law or regulation to close in New York, New York. 
 A “Trading Day” with respect to an Index Component means a day, as determined by the Calculation Agent, on which (i) the Relevant Exchanges with respect to each security underlying
such Index Component are scheduled to be open for trading for their respective regular trading sessions and (ii) each Related Exchange is scheduled to be open for trading for its regular trading session. The “Relevant Exchange”
for any security underlying an Index Component means the primary exchange or quotation system on which such security is traded, as determined by the Calculation Agent. The “Related Exchange” for an Index Component means each
exchange or quotation system where trading has a material effect (as determined by the Calculation Agent) on the overall market for futures or options contracts relating to such Index Component. 

A “Trading Day” with respect to an ETF Component means a day, as determined by the Calculation Agent, on
which the Relevant Exchange and each Related Exchange with respect to such ETF Component, or any successor thereto, if applicable, are scheduled to be open for trading for their respective regular trading sessions. The “Related
Exchange” for an ETF Component means each exchange or quotation system where trading has a material effect (as determined by the Calculation Agent) on the overall market for futures or options contracts relating to such ETF Component. The
“Relevant Exchange” for an ETF Component means the primary exchange or quotation system on which shares (or other applicable securities) of such ETF Component are traded, as determined by the Calculation Agent. 

The “Calculation Day” shall be July 5, 2017. If the scheduled Calculation Day is not a Trading Day
with respect to any Basket Component, the Calculation Day for such Basket Component will be postponed to the next succeeding day that is a Trading Day with respect to such Basket Component. In addition, the Calculation Day is subject to postponement
due to the 

  
 4 

 
occurrence of a Market Disruption Event. If a Market Disruption Event occurs or is continuing with respect to a Basket Component on the Calculation Day, then the Calculation Day for such Basket
Component will be postponed to the first succeeding Trading Day for such Basket Component on which a Market Disruption Event for such Basket Component has not occurred and is not continuing. If such first succeeding Trading Day has not occurred as
of the eighth Trading Day for such Basket Component after the originally scheduled Calculation Day for such Basket Component, that eighth Trading Day shall be deemed the Calculation Day. If the Calculation Day has been postponed eight Trading Days
for a Basket Component after the originally scheduled Calculation Day for such Basket Component, and a Market Disruption Event occurs or is continuing with respect to such Basket Component on such eighth Trading Day, the Calculation Agent will
(i) in the case of an Index Component, determine the Closing Level of such Index Component on such eighth Trading Day in accordance with the formula for and method of calculating the Closing Level of such Index Component last in effect prior to
commencement of the Market Disruption Event, using the closing price (or, with respect to any of the relevant securities, if a Market Disruption Event has occurred, its good faith estimate of the value of such securities at the Scheduled Closing
Time (as defined below) on the Relevant Exchanges) on such date of each security included in such Index Component and (ii) in the case of an ETF Component, determine the Closing Price of such ETF Component on such eighth Trading Day based on
its good faith estimate of the value of the shares (or other applicable securities) of such ETF Component as of the Close of Trading (as defined below) on such eighth Trading Day. Notwithstanding a postponement of the Calculation Day for a
particular Basket Component due to a Market Disruption Event with respect to such Basket Component, the originally scheduled Calculation Day will remain the Calculation Day for any Basket Component not affected by a Market Disruption Event. As used
in clause (i) of the second preceding sentence, “closing price” means, with respect to any security on any date, the Relevant Exchange traded or quoted price of such security as of the Close of Trading (as defined below) on
such date. 
 “Calculation Agent Agreement” shall mean the Calculation Agent Agreement dated as
of May 29, 2012 between the Company and the Calculation Agent, as amended from time to time. 

“Calculation Agent” shall mean the Person that has entered into the Calculation Agent Agreement with the
Company providing for, among other things, the determination of the Ending Price and the Redemption Amount, which term shall, unless the context otherwise requires, include its successors under such Calculation Agent Agreement. The initial
Calculation Agent shall be Wells Fargo Securities, LLC. Pursuant to the Calculation Agent Agreement, the Company may appoint a different Calculation Agent from time to time after the initial issuance of this Security without the consent of the
Holder of this Security and without notifying the Holder of this Security. 
 Market Disruption Events 

A “Market Disruption Event” means, with respect to an Index Component, any of the following events as
determined by the Calculation Agent in its sole discretion: 
  

	 	(A)	 The occurrence or existence of a material suspension of or limitation imposed on trading by the Relevant Exchanges or otherwise relating to
securities which then 

  
 5 

	 	 
comprise 20% or more of the level of such Index Component or any Successor Equity Index Component (as defined below) at any time during the one-hour period that ends at the Close of Trading on
that day, whether by reason of movements in price exceeding limits permitted by those Relevant Exchanges or otherwise. 

  

	 	(B)	 The occurrence or existence of a material suspension of or limitation imposed on trading by any Related Exchange or otherwise in futures or options
contracts relating to such Index Component or any Successor Equity Index Component on any Related Exchange at any time during the one-hour period that ends at the Close of Trading on that day, whether by reason of movements in price exceeding limits
permitted by the Related Exchange or otherwise. 

  

	 	(C)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the ability of market participants in
general to effect transactions in, or obtain market values for, securities that then comprise 20% or more of the level of such Index Component or any Successor Equity Index Component on their Relevant Exchanges at any time during the one-hour period
that ends at the Close of Trading on that day. 

  

	 	(D)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the ability of market participants in
general to effect transactions in, or obtain market values for, futures or options contracts relating to such Index Component or any Successor Equity Index Component on any Related Exchange at any time during the one-hour period that ends at the
Close of Trading on that day. 

  

	 	(E)	 The closure on any Exchange Business Day (as defined below) of the Relevant Exchanges on which securities that then comprise 20% or more of the
level of such Index Component or any Successor Equity Index Component are traded or any Related Exchange prior to its Scheduled Closing Time unless the earlier closing time is announced by the Relevant Exchange or Related Exchange, as applicable, at
least one hour prior to the earlier of (1) the actual closing time for the regular trading session on such Relevant Exchange or Related Exchange, as applicable, and (2) the submission deadline for orders to be entered into the Relevant
Exchange or Related Exchange, as applicable, system for execution at the Close of Trading on that day. 

  

	 	(F)	 The Relevant Exchange for any security underlying such Index Component or Successor Equity Index Component or any Related Exchange fails to open for
trading during its regular trading session. 

 For purposes of determining whether a Market
Disruption Event has occurred with respect to an Index Component: 
  

	 	(1)	 the relevant percentage contribution of a security to the level of such Index Component or any Successor Equity Index Component will be based on a

  
 6 

	 	 
comparison of (x) the portion of the level of such Index Component attributable to that security and (y) the overall level of such Index Component or Successor Equity Index Component,
in each case immediately before the occurrence of the Market Disruption Event; 

  

	 	(2)	 the “Close of Trading” means the Scheduled Closing Time of the Relevant Exchanges with respect to the securities underlying such
Index Component or any Successor Equity Index Component; 

  

	 	(3)	 the “Scheduled Closing Time” of any Relevant Exchange or Related Exchange on any Trading Day for such Index Component or any
Successor Equity Index Component means the scheduled weekday closing time of such Relevant Exchange or Related Exchange on such Trading Day, without regard to after hours or any other trading outside the regular trading session hours; and

  

	 	(4)	 an “Exchange Business Day” means any Trading Day for such Index Component or any Successor Equity Index Component on which each
Relevant Exchange for the securities underlying such Index Component or any Successor Equity Index Component and each Related Exchange are open for trading during their respective regular trading sessions, notwithstanding any such Relevant Exchange
or Related Exchange closing prior to its Scheduled Closing Time. 

 A “Market
Disruption Event” means, with respect to an ETF Component, any of the following events as determined by the Calculation Agent in its sole discretion: 
  

	 	(A)	 The occurrence or existence of a material suspension of or limitation imposed on trading by the Relevant Exchange or otherwise relating to the
shares (or other applicable securities) of such ETF Component or any Successor ETF Component (as defined below) on the Relevant Exchange at any time during the one-hour period that ends at the Close of Trading on such day, whether by reason of
movements in price exceeding limits permitted by such Relevant Exchange or otherwise. 

  

	 	(B)	 The occurrence or existence of a material suspension of or limitation imposed on trading by any Related Exchange or otherwise in futures or options
contracts relating to the shares (or other applicable securities) of such ETF Component or any Successor ETF Component on any Related Exchange at any time during the one-hour period that ends at the Close of Trading on that day, whether by reason of
movements in price exceeding limits permitted by the Related Exchange or otherwise. 

  

	 	(C)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the ability of market participants in
general to effect transactions in, or obtain market values for, shares (or other applicable securities) of such ETF Component or any Successor ETF Component on the Relevant Exchange at any time during the one-hour period that ends at the Close of
Trading on that day. 

  
 7 

	 	(D)	 The occurrence or existence of any event, other than an early closure, that materially disrupts or impairs the ability of market participants in
general to effect transactions in, or obtain market values for, futures or options contracts relating to shares (or other applicable securities) of such ETF Component or any Successor ETF Component on any Related Exchange at any time during the
one-hour period that ends at the Close of Trading on that day. 

  

	 	(E)	 The closure of the Relevant Exchange or any Related Exchange with respect to such ETF Component or any Successor ETF Component prior to its
Scheduled Closing Time unless the earlier closing time is announced by the Relevant Exchange or Related Exchange, as applicable, at least one hour prior to the earlier of (1) the actual closing time for the regular trading session on such
Relevant Exchange or Related Exchange, as applicable, and (2) the submission deadline for orders to be entered into the Relevant Exchange or Related Exchange, as applicable, system for execution at the Close of Trading on that day.

  

	 	(F)	 The Relevant Exchange or any Related Exchange with respect to such ETF Component or any Successor ETF Component fails to open for trading during its
regular trading session. 

 For purposes of determining whether a Market Disruption Event has
occurred with respect to an ETF Component: 
  

	 	(1)	 “Close of Trading” means the Scheduled Closing Time of the Relevant Exchange with respect to such ETF Component or any Successor
ETF Component; and 

  

	 	(2)	 the “Scheduled Closing Time” of the Relevant Exchange or any Related Exchange on any Trading Day for such ETF Component or any
Successor ETF Component means the scheduled weekday closing time of such Relevant Exchange or Related Exchange on such Trading Day, without regard to after hours or any other trading outside the regular trading session hours.

 Adjustments To An Index Component 

If at any time a sponsor or publisher of an Index Component (each, an “Index Sponsor”) makes a material
change in the formula for or the method of calculating such Index Component, or in any other way materially modifies such Index Component (other than a modification prescribed in that formula or method to maintain such Index Component in the event
of changes in constituent stock and capitalization and other routine events), then, from and after that time, the Calculation Agent will, at the close of business in New York, New York, on each date that the Closing Level of such Index Component is
to be calculated, calculate a substitute Closing Level of such Index Component in accordance with the formula for and method of calculating such Index Component last in effect prior to the change, but using only those securities that comprised such
Index Component immediately prior to that change. Accordingly, if the method of calculating an Index Component is modified so that the level of such Index Component is a fraction or a multiple of what it would have been if it had not been modified,
then the 

  
 8 

 
Calculation Agent will adjust such Index Component in order to arrive at a level of such Index Component as if it had not been modified. 
 Discontinuance Of An Index Component 
 If an Index
Sponsor discontinues publication of the relevant Index Component, and such Index Sponsor or another entity publishes a successor or substitute equity index that the Calculation Agent determines, in its sole discretion, to be comparable to such Index
Component (a “Successor Equity Index Component”), then, upon the Calculation Agent’s notification of that determination to the Trustee and the Company, the Calculation Agent will substitute the Successor Equity Index Component
as calculated by the relevant Index Sponsor or any other entity and calculate the Ending Price as described above. Upon any selection by the Calculation Agent of a Successor Equity Index Component, the Company will cause notice to be given to the
Holder of this Security. 
 In the event that an Index Sponsor of an Index Component discontinues publication of
the relevant Index Component prior to, and the discontinuance is continuing on, the Calculation Day and the Calculation Agent determines that no Successor Equity Index Component is available at such time, the Calculation Agent will calculate a
substitute Closing Level for such Index Component in accordance with the formula for and method of calculating such Index Component last in effect prior to the discontinuance, but using only those securities that comprised such Index Component
immediately prior to that discontinuance. If a Successor Equity Index Component is selected or the Calculation Agent calculates a level as a substitute for an Index Component, the Successor Equity Index Component or level will be used as a
substitute for such Index Component for all purposes, including the purpose of determining whether a Market Disruption Event exists. 
 If on the Calculation Day an Index Sponsor of an Index Component fails to calculate and announce the level of such Index Component, the Calculation Agent will calculate a substitute Closing Level of such
Index Component in accordance with the formula for and method of calculating such Index Component last in effect prior to the failure, but using only those securities that comprised such Index Component immediately prior to that failure;
provided that, if a Market Disruption Event occurs or is continuing with respect to such Index Component on such day, then the provisions set forth above under the definition of “Calculation Day” shall apply in lieu of the
foregoing. 
 Anti-dilution Adjustments Relating To An ETF Component; Alternate Calculation 

Anti-dilution Adjustments 
 The Calculation Agent will adjust the Adjustment Factor with respect to an ETF Component as specified below if any of the events specified below occurs with respect to such ETF Component and the effective
date or ex-dividend date, as applicable, for such event is after the Pricing Date and on or prior to the Calculation Day. 
 The adjustments specified below do not cover all events that could affect an ETF Component. The Calculation Agent may, in its sole discretion, make additional adjustments to

  
 9 

 
any terms of this Security upon the occurrence of other events that affect or could potentially affect the market price of, or shareholder rights in, such ETF Component, with a view to
offsetting, to the extent practical, any such change, and preserving the relative investment risks of this Security. In addition, the Calculation Agent may, in its sole discretion, make adjustments or a series of adjustments that differ from those
described herein if the Calculation Agent determines that such adjustments do not properly reflect the economic consequences of the events specified herein or would not preserve the relative investment risks of this Security. All determinations made
by the Calculation Agent in making any adjustments to the terms of this Security, including adjustments that are in addition to, or that differ from, those described herein, will be made in good faith and a commercially reasonable manner, with the
aim of ensuring an equitable result. In determining whether to make any adjustment to the terms of this Security, the Calculation Agent may consider any adjustment made by the Options Clearing Corporation or any other equity derivatives clearing
organization on options contracts on the affected ETF Component. 
 For any event described below, the
Calculation Agent will not be required to adjust the Adjustment Factor unless the adjustment would result in a change to the Adjustment Factor then in effect of at least 0.10%. The Adjustment Factor resulting from any adjustment will be rounded up
or down, as appropriate, to the nearest one-hundred thousandth. 
  

	 	(A)	 Stock Splits and Reverse Stock Splits  

If a stock split or reverse stock split has occurred, then once such split has become effective, the Adjustment Factor
will be adjusted to equal the product of the prior Adjustment Factor and the number of securities which a holder of one share (or other applicable security) of the ETF Component before the effective date of such stock split or reverse stock split
would have owned or been entitled to receive immediately following the applicable effective date. 
  

	 	(B)	 Stock Dividends  

 If a dividend or distribution of shares (or other applicable securities) to which this Security is linked has been made by an ETF Component ratably to all holders of record of such shares (or other
applicable security), then the Adjustment Factor will be adjusted on the ex-dividend date to equal the prior Adjustment Factor plus the product of the prior Adjustment Factor and the number of shares (or other applicable security) of such ETF
Component which a holder of one share (or other applicable security) of such ETF Component before the ex-dividend date would have owned or been entitled to receive immediately following that date; provided, however, that no adjustment will be made
for a distribution for which the number of securities of such ETF Component paid or distributed is based on a fixed cash equivalent value. 
  

	 	(C)	 Extraordinary Dividends  

 If an Extraordinary Dividend (as defined below) has occurred, then the Adjustment Factor will be adjusted on the ex-dividend date to equal the product

  
 10 

 
of the prior Adjustment Factor and a fraction, the numerator of which is the Closing Price per share (or other applicable security) of such ETF Component on the Trading Day preceding the
ex-dividend date, and the denominator of which is the amount by which the Closing Price per share (or other applicable security) of such ETF Component on the Trading Day preceding the ex-dividend date exceeds the Extraordinary Dividend Amount (as
defined below). 
 For purposes of determining whether an Extraordinary Dividend has occurred: 

 

	 	(1)	 “Extraordinary Dividend” means any cash dividend or distribution (or portion thereof) that the Calculation Agent determines, in its
sole discretion, is extraordinary or special; and 

  

	 	(2)	 “Extraordinary Dividend Amount” with respect to an Extraordinary Dividend for the securities of such ETF Component will equal the
amount per share (or other applicable security) of such ETF Component of the applicable cash dividend or distribution that is attributable to the Extraordinary Dividend, as determined by the Calculation Agent in its sole discretion.

 A distribution on the securities of such ETF Component described below under the section
entitled “—Reorganization Events” below that also constitutes an Extraordinary Dividend will only cause an adjustment pursuant to that “—Reorganization Events” section. 

 

	 	(D)	 Other Distributions  

 If an ETF Component declares or makes a distribution to all holders of the shares (or other applicable security) of such ETF Component of any non-cash assets, excluding dividends or distributions
described under the section entitled “—Stock Dividends” above, then the Calculation Agent may, in its sole discretion, make such adjustment (if any) to the Adjustment Factor as it deems appropriate in the circumstances. If the
Calculation Agent determines to make an adjustment pursuant to this paragraph, it will do so with a view to offsetting, to the extent practical, any change in the economic position of a holder of this Security that results solely from the applicable
event. 
  

	 	(E)	 Reorganization Events  

 If an ETF Component, or any Successor ETF Component, is subject to a merger, combination, consolidation or statutory exchange of securities with another exchange traded fund, and such ETF Component to
which this Security is linked is not the surviving entity (a “Reorganization Event”), then, on or after the date of such event, the Calculation Agent shall, in its sole discretion, make an adjustment to the Adjustment Factor or the
method of determining the Redemption Amount or any other terms of this Security as the Calculation Agent determines appropriate to account for the economic effect on this Security of such event, and

  
 11 

 
determine the effective date of that adjustment. If the Calculation Agent determines that no adjustment that it could make will produce a commercially reasonable result, then the Calculation
Agent may deem such event a Liquidation Event (as defined below). 
 Liquidation Events 

If an ETF Component is de-listed, liquidated or otherwise terminated (a “Liquidation Event”), and a
successor or substitute exchange traded fund exists that the Calculation Agent determines, in its sole discretion, to be comparable to such ETF Component, then, upon the Calculation Agent’s notification of that determination to the Trustee and
the Company, any subsequent Fund Closing Price for such ETF Component will be determined by reference to the Fund Closing Price of such successor or substitute exchange traded fund (such exchange traded fund being referred to herein as a
“Successor ETF Component”), with such adjustments as the Calculation Agent determines are appropriate to account for the economic effect of such substitution on the holder of this Security. 

If an ETF Component undergoes a Liquidation Event prior to, and such Liquidation Event is continuing on, the date that
any Fund Closing Price of such ETF Component is to be determined and the Calculation Agent determines that no Successor ETF Component is available at such time, then the Calculation Agent will, in its discretion, calculate the Fund Closing Price for
such ETF Component on such date by a computation methodology that the Calculation Agent determines will as closely as reasonably possible replicate such ETF Component, provided that if the Calculation Agent determines in its discretion that it is
not practicable to replicate such ETF Component (including but not limited to the instance in which the sponsor of the index underlying such ETF Component discontinues publication of that index), then the Calculation Agent will calculate the Fund
Closing Price for such ETF Component in accordance with the formula last used to calculate such Fund Closing Price before such Liquidation Event, but using only those securities that were held by such ETF Component immediately prior to such
Liquidation Event without any rebalancing or substitution of such securities following such Liquidation Event. 

If a Successor ETF Component is selected or the Calculation Agent calculates the Fund Closing Price as a substitute for
such ETF Component, such Successor ETF Component or Fund Closing Price will be used as a substitute for such ETF Component for all purposes, including for purposes of determining whether a Market Disruption Event exists. 

If any event is both a Reorganization Event and a Liquidation Event, such event will be treated as a Reorganization Event
for purposes of this Security unless the Calculation Agent makes the determination referenced in the last sentence of the section entitled “—Anti-dilution Adjustments—Reorganization Events” above. 

Alternate Calculation 
 If at any time the method of calculating an ETF Component or a Successor ETF Component, or the related Underlying Index, is changed in a material respect, or if an ETF Component or a Successor ETF
Component is in any other way modified so that such ETF 

  
 12 

 
Component does not, in the opinion of the Calculation Agent, fairly represent the price of the securities of such ETF Component or such Successor ETF Component had such changes or modifications
not been made, then the Calculation Agent may, at the close of business in New York City on the date that any Fund Closing Price is to be determined, make such calculations and adjustments as, in the good faith judgment of the Calculation Agent, may
be necessary in order to arrive at a Closing Price of an exchange traded fund comparable to such ETF Component or such Successor ETF Component, as the case may be, as if such changes or modifications had not been made, and calculate the Fund Closing
Price and the Redemption Amount with reference to such adjusted Closing Price of such ETF Component or such Successor ETF Component, as applicable. 
 Calculation Agent 
 The Calculation Agent will
determine the Redemption Amount and the Ending Price. In addition, the Calculation Agent will (i) determine whether a Market Disruption Event has occurred, (ii) determine if adjustments are required to the Closing Level of an Index
Component under various circumstances, (iii) if publication of an Index Component is discontinued, select a Successor Equity Index Component or, if no Successor Equity Index Component is available, determine the Closing Level of such Index
Component, (iv) determine if adjustments are required to the Fund Closing Price of an ETF Component under various circumstances; and (v) if an ETF Component undergoes a Liquidation Event, select a Successor ETF Component or, if no
Successor ETF Component is available, determine the Fund Closing Price for such ETF Component. 
 The Company
covenants that, so long as this Security is Outstanding, there shall at all times be a Calculation Agent (which shall be a broker-dealer, bank or other financial institution) with respect to this Security. 

All determinations made by the Calculation Agent with respect to this Security will be at the sole discretion of the
Calculation Agent and, in the absence of manifest error, will be conclusive for all purposes and binding on the Company and the Holder of this Security. All percentages and other amounts resulting from any calculation with respect to this Security
will be rounded at the Calculation Agent’s discretion. 
 Redemption and Repayment 

This Security is not subject to redemption at the option of the Company or repayment at the option of the Holder hereof
prior to July 10, 2017. This Security is not entitled to any sinking fund. 
 Acceleration 

If an Event of Default, as defined in the Indenture, with respect to this Security shall occur and be continuing, the
Redemption Amount (calculated as set forth in the next sentence) of this Security may be declared due and payable in the manner and with the effect provided in the Indenture. The amount payable to the Holder hereof upon any acceleration permitted
under the Indenture will be equal to the Redemption Amount hereof calculated as provided herein; provided, however, that the Redemption Amount will be calculated using the Closing Levels and Closing Prices, as applicable, of the Basket Components on
the date of acceleration. 

  
 13 

   

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further
provisions shall for all purposes have the same effect as if set forth at this place. 
 Unless the certificate
of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature or its duly authorized agent under the Indenture referred to on the reverse hereof by manual signature, this Security shall not be
entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 
 [The remainder of this page has been
left intentionally blank] 

  
 14 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed under its corporate seal. 
 DATED:
                     
  

					
	 WELLS FARGO & COMPANY

			
	 By:
	 	 	 	 
			
		 	 	 	 
		 	 Its:
	 	 

 [SEAL] 
  

					
			
	 Attest:
	 	 	 	 
			
		 	 	 	 
		 	 Its:
	 	 

 TRUSTEE’S CERTIFICATE OF 

AUTHENTICATION 

This is one of the Securities of the 
 series designated therein described 
 in the within-mentioned Indenture.

  

			
	 CITIBANK, N.A.,
       as Trustee

		
	 By:
	 	 
		 	 Authorized Signature

 OR 
  

			
	 WELLS FARGO BANK, N.A.,
     as Authenticating Agent for the Trustee

		
	 By:
	 	 
		 	 Authorized Signature

  
 15 

 [Reverse of Note] 
 WELLS FARGO & COMPANY 
 MEDIUM-TERM NOTE, SERIES K

 Due Nine Months or More From Date of Issue 
 Securities Linked to a Global Basket of Equity Indices and ETFs 
 due
July 10, 2017 
 This Security is one of a duly authorized issue of securities of the Company (herein
called the “Securities”), issued and to be issued in one or more series under an indenture dated as of July 21, 1999, as amended or supplemented from time to time (herein called the “Indenture”), between the
Company and Citibank, N.A., as Trustee (herein called the “Trustee,” which term includes any successor trustee under the Indenture), to which Indenture and all indentures supplemental thereto reference is hereby made for a statement
of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon which the Securities are, and are to be, authenticated and delivered. This
Security is one of the series of the Securities designated as Medium-Term Notes, Series K, of the Company, which series is limited to an aggregate principal amount or face amount, as applicable, of $25,000,000,000 or the equivalent thereof in one or
more foreign or composite currencies. The amount payable on the Securities of this series may be determined by reference to the performance of one or more equity-, commodity- or currency-based indices, exchange traded funds, securities, commodities,
currencies, statistical measures of economic or financial performance, or a basket comprised of two or more of the foregoing, or any other market measure or may bear interest at a fixed rate or a floating rate. The Securities of this series may
mature at different times, be redeemable at different times or not at all, be repayable at the option of the Holder at different times or not at all and be denominated in different currencies. 

Article Sixteen of the Indenture shall not apply to this Security. 

The Securities are issuable only in registered form without coupons and will be either (a) book-entry securities
represented by one or more Global Securities recorded in the book-entry system maintained by the Depositary or (b) certificated securities issued to and registered in the names of, the beneficial owners or their nominees. 

The Company agrees, to the extent permitted by law, not to voluntarily claim the benefits of any laws concerning usurious
rates of interest against a Holder of this Security. 
 Modification and Waivers 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the
rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of
the Securities at the 

  
 16 

 
time Outstanding of all series to be affected, acting together as a class. The Indenture also contains provisions permitting the Holders of a majority in principal amount of the Securities of all
series at the time Outstanding affected by certain provisions of the Indenture, acting together as a class, on behalf of the Holders of all Securities of such series, to waive compliance by the Company with those provisions of the Indenture. Certain
past defaults under the Indenture and their consequences may be waived under the Indenture by the Holders of a majority in principal amount of the Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such
series. Solely for the purpose of determining whether any consent, waiver, notice or other action or Act to be taken or given by the Holders of Securities pursuant to the Indenture has been given or taken by the Holders of Outstanding Securities in
the requisite aggregate principal amount, the principal amount of this Security will be deemed to be equal to the amount set forth on the face hereof as the “Face Amount” hereof. Any such consent or waiver by the Holder of this Security
shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or
waiver is made upon this Security. 
 Defeasance 

Section 403 and Article Fifteen of the Indenture and the provisions of clause (ii) of Section 401(1)(B) of
the Indenture, relating to defeasance at any time of (a) the entire indebtedness on this Security and (b) certain restrictive covenants and certain Events of Default, upon compliance by the Company with certain conditions set forth
therein, shall not apply to this Security. The remaining provisions of Section 401 of the Indenture shall apply to this Security. 

Authorized Denominations 
 This Security is issuable only in registered form without coupons in denominations of $1,000 or any amount in excess thereof which is an integral multiple of $1,000. 

Registration of Transfer 
 Upon due presentment for registration of transfer of this Security at the office or agency of the Company in the City of Minneapolis, Minnesota, a new Security or Securities of this series, with the same
terms as this Security, in authorized denominations for an equal aggregate Face Amount will be issued to the transferee in exchange herefor, as provided in the Indenture and subject to the limitations provided therein and to the limitations
described below, without charge except for any tax or other governmental charge imposed in connection therewith. 
 This Security is exchangeable for definitive Securities in registered form only if (x) the Depositary notifies the Company that it is unwilling or unable to continue as Depositary for this Security
or if at any time the Depositary ceases to be a clearing agency registered under the Securities Exchange Act of 1934, as amended, and a successor depositary is not appointed within 90 days after the Company receives such notice or becomes aware
of such ineligibility, (y) the Company in its sole discretion determines that this Security shall be exchangeable for definitive Securities in registered form and notifies the Trustee thereof or (z) an Event of Default with respect to the
Securities represented hereby has occurred and is continuing. If this Security is exchangeable pursuant to the preceding sentence, it shall be exchangeable for definitive Securities in registered

  
 17 

 
form, having the same date of issuance, Stated Maturity Date and other terms and of authorized denominations aggregating a like amount. 

This Security may not be transferred except as a whole by the Depositary to a nominee of the Depositary or by a nominee
of the Depositary to the Depositary or another nominee of the Depositary or by the Depositary or any such nominee to a successor of the Depositary or a nominee of such successor. Except as provided above, owners of beneficial interests in this
Global Security will not be entitled to receive physical delivery of Securities in definitive form and will not be considered the Holders hereof for any purpose under the Indenture. 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the
Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice
to the contrary. 
 Obligation of the Company Absolute 

No reference herein to the Indenture and no provision of this Security or the Indenture shall alter or impair the
obligation of the Company, which is absolute and unconditional, to pay the Redemption Amount at the times, place and rate, and in the coin or currency, herein prescribed, except as otherwise provided in this Security. 

No Personal Recourse 
 No recourse shall be had for the payment of the Redemption Amount, or for any claim based hereon, or otherwise in respect hereof, or based on or in respect of the Indenture or any indenture supplemental
thereto, against any incorporator, stockholder, officer or director, as such, past, present or future, of the Company or any successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any
assessment or penalty or otherwise, all such liability being, by the acceptance hereof and as part of the consideration for the issuance hereof, expressly waived and released. 
 Defined Terms 
 All terms used in this Security
which are defined in the Indenture shall have the meanings assigned to them in the Indenture unless otherwise defined in this Security. 

Governing Law 
 This Security shall be governed by and construed in accordance with the law of the State of New York, without regard to principles of conflicts of laws. 

  
 18 

 ABBREVIATIONS 

The following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though
they were written out in full according to applicable laws or regulations: 
  

							
	 TEN COM
	 	--	    	as tenants in common	  	
				
	 TEN ENT
	 	--	    	as tenants by the entireties	  	
				
	 JT TEN
	 	--	    	 as joint tenants with right
 of
survivorship and not
 as tenants in common
	  	

  

							
	 UNIF GIFT MIN ACT --    
	    	 	 	Custodian	 	 
		    	(Cust)	 		 	(Minor)

  

	
	Under Uniform Gifts to Minors Act
	
	  
	(State)

 Additional abbreviations may also be used though not in the above list. 

FOR VALUE RECEIVED, the undersigned hereby sell(s) and transfer(s) unto 

 

	
	 Please Insert Social Security or
 Other Identifying Number of Assignee

	
	  

  
  
  

 
  
  

 
  
  

 
 (PLEASE
PRINT OR TYPE NAME AND ADDRESS INCLUDING POSTAL ZIP CODE OF ASSIGNEE)

  
 19 

 
the within Security of WELLS FARGO & COMPANY and does hereby irrevocably constitute and appoint __________________ attorney to transfer the said Security on the books of the Company,
with full power of substitution in the premises. 
 Dated: _________________________ 

 

	
	
	  
	
	  

  
 NOTICE: The signature to this
assignment must correspond with the name as written upon the face of the within instrument in every particular, without alteration or enlargement or any change whatever. 

  
 20EX-10.1

 Exhibit 10.1 

 

			
	

	  	Master Supply and Distribution Agreement

 Master Supply and Distribution Agreement 

 

			
	Supplier 	  	Company 
		
	Milestone Scientific, Inc. and	  	Tri-anim Health Services, Inc.
	220 South Orange Avenue	  	5000 Tuttle Crossing Boulevard
	Livingston, New Jersey 07039	  	Dublin, Ohio 43016
	Attention: Leonard Osser, CEO	  	Attention: Jeffrey Prestel, President
	Telephone: 973-535-2717	  	Telephone: 614.760.5008
	Facsimile: 973-535-2829	  	Facsimile: 614.760.0533
	E-mail: losser@milestonescientific.com	  	E-mail: jeff.prestel@sarnova.com

  

	1.	Scope of Agreement. 

  

	 	1.1.	Supply and Purchase Products. Subject to the terms and conditions set forth herein, Supplier shall make available the Products (as defined below) for purchase by
Company and Company shall purchase from Supplier the Products it orders under this Master Agreement. 

  

	 	1.2.	Appointment of Company. Subject to the terms and conditions set forth in this Master Agreement, Supplier hereby appoints Company during the Term (as defined
below) as its exclusive distributor of the Exclusive Products within the Territory (as defined below), authorized to market, resell, label under its own private label, and distribute the Products to Company’s customers within the Territory and.
During the Term, no other entity, including without limitation Supplier, shall market, resell, label, or distribute Exclusive Products, within the Territory. For this purpose, the limitation on other entities shall apply to the Exclusive Products
regardless of whether the Products are labeled with Company’s label or any other label. 

  

	2.	Definitions. The following terms, when capitalized in this Agreement, shall have the meanings set forth below: 

 

	 	2.1.	“Agreement” means this Master Agreement together with any purchase order issued hereunder during the Term. 

 

	 	2.2.	“Claims” means all claims, liability, damage, losses, or expenses, including litigation costs and attorneys’ fees. 

 

	 	2.3.	“Company Party” or “Company Parties” means Company and its affiliates, and each of their officers, members, shareholders, directors, employees,
agents, and contractors. 

  
 1 

			
	

	  	Master Supply and Distribution Agreement

  

	 	2.4.	“Confidential Information” means any proprietary or confidential information, technical data, trade secrets or know-how, including, but not limited to,
research, product plans, products, services, customer lists and customers, markets, software, developments, inventions, processes, formulas, technology, designs, drawings, engineering, marketing, distribution and sales methods and systems, sales and
profit figures, forecasts and inventory information, finances and other information belonging to a Party. Sales tracing reports shall be considered the Confidential Information of Company. However, Confidential Information does not include any of
the foregoing items which (i) has become publicly known and made generally available through no act of the Receiving Party; (ii) is developed by the Receiving Party without use of the Confidential Information of the Disclosing Party;
(iii) is disclosed to the Receiving Party by a third party who is not under an obligation to preserve its confidentiality; or (iv) is required to be disclosed pursuant to any applicable laws, provided that the Receiving Party shall give
the Disclosing Party reasonable prior written notice of any such anticipated disclosure and shall cooperate with the Disclosing Party’s efforts to obtain a protective order. 

 

	 	2.5.	“Contract Year” means each twelve (12) month period during the Term of this Agreement, commencing on the Effective Date. 

 

	 	2.6.	“Delivery Date” means the date specified in the Purchase order as of which the entire order is scheduled to be received by Company; provided, however, that in
no event shall the Delivery Date be less than 5 days from the date of the Purchase Order. 

  

	 	2.7.	“Disclosing Party” means the Party disclosing information to the other Party. 

 

	 	2.8.	“Exclusive Products” means those Products designated on Exhibit A as Exclusive Products. 

 

	 	2.9.	“Effective Date” shall be the same date in which the FDA approves the 510K of the products. 

 

	 	2.10.	“Fill Rate” means the quantity of fully conforming Products actually shipped within the Lead Time, divided by the quantity of conforming Products that should
have been shipped by the Delivery Date. Fill Rate is determined on a purchase order basis. 

  

	 	2.11.	“GP Dollars” means the difference between the price at which Product is sold by Company to its customers and the price at which that Product is sold by
Supplier to Company. For this purpose price is determined without regard to the application of any discounts or rebates. 

  

	 	2.12.	“GPO” means Group Purchasing Organization. 

  

	 	2.13.	“Mandatory Fill Rate” means with respect to a given order, 98% Fill Rate. 

 

	 	2.14.	“Party” or “Parties” means the Supplier and/or Company, as the context shall require. 

 

	 	2.15.	“Private Label Products” means all Products identified on Exhibit A as Private Label Products. 

 

	 	2.16.	“Products” means the products identified on Exhibit A hereto. Products may be added or deleted to Exhibit A by a mutually signed written
agreement of the Parties. Products shall include all manuals, usage instructions and limitations, safety devices, and safety information applicable to such Products. The term “Products” includes all Exclusive Products.

  
 2 

			
	

	  	Master Supply and Distribution Agreement

  

	 	2.17.	“Receiving Party” means the Party that is the recipient of information from the Disclosing Party. 

 

	 	2.18.	“Term” means the period beginning on the Effective Date and continuing for a period of 3 years, unless earlier terminated in accordance with Section 15.
If not terminated earlier, the Term will be extended for additional one-year periods, unless one Party notifies the other Party in writing of its intention not to extend the Term at least 120 days prior to the end of the then current Term. The
initial term together with any extensions thereof are referred to in the aggregate as “Term.” 

  

	 	2.19.	“Territory” means the United States of America, including all possessions and territories and United States government and military facilities operating
outside of the United States of America. 

  

	 	2.20.	“Market” means health care facilities, home health care market, acute care market, long-term acute care and US government acute care facilities. We define the
Tri-anim market as Acute Care only at this time and exclude free-standing, non-hospital affiliated pain management clinics and private pain practices. 

  

	3.	Product Orders and Quantity. 

  

	 	3.1.	Purchase Orders. Company shall submit to Supplier a purchase order for each order of Products hereunder via facsimile on its standard purchase order form, the
terms and conditions of which are incorporated herein by reference, to the extent such terms and conditions do not conflict with the terms and conditions of this Master Agreement. To the extent there is a conflict, the terms and conditions of this
Master Agreement will prevail. 

  

	 	3.2.	Quantity. The minimum purchase quantity for year one of the contract is five hundred (500) CompuFlo instruments, excluding disposable circuits, which shall
be purchased for shipment over the course of the first 18 months following FDA approval of the products’ 510K. The minimum purchase quantity for year two of and for year three of the contract will be determined by negotiation between the
Parties at least 60 days prior to the commencement of year two or year three of the contract. If the Company does not purchase the minimum purchase quantity in any year or if the Parties fail to agree on the minimum purchase quantity for years two
or three, the Supplier, as its sole and exclusive remedy, can terminate the contract upon 120 days’ notice. 

  

	 	3.3.	Down Payment. Company will provide a down payment of $100,000 within 30 days of FDA approval of the 510K for CompuFlo instrument and corresponding disposable
circuit. Company’s down payment will be applied directly towards future purchases from Supplier. 

  
 3 

			
	

	  	Master Supply and Distribution Agreement

  

	4.	Pricing, Invoices, and Payment Terms. 

  

	 	4.1.	Pricing. Prices for products ordered by distributor shall be set forth on Exhibit A hereto. All prices shall remain firm for the Term, subject only to
change once per year, with a maximum increase of three (3) percent. All pricing increases must be submitted with 90 days advance notice and agreed upon by Company following verification of material cost increases provided by supplier as no
arbitrary price increases will be accepted by Company. 

  

	 	4.2.	Taxes, Freight, and other Costs. Other than any applicable sales tax relating to Products, Supplier shall bear the cost of any taxes relating to the Products
and/or the supply thereof, including, without limitation, any use, customs, import, medical device tax or excise tax. The Company shall bear the cost of freight, FOB destination freight collect, and all other shipment and delivery costs including,
packaging, carrier costs, and additional cost for expedited shipments for all disposable units, which will be warehoused at Tri-anim warehouse facilities before being sent to customers. Supplier shall procure insurance to protect against risk of
loss and/or damage until title to Products transfers to Company. All capital units will be drop shipped by the Supplier directly to the end-user customer in a timely fashion upon notification of a customer purchase. Company will procure and maintain
inventory on all disposable units based on customer demand creation. Title of Products and liability for Products shall transfer to Company only upon Company or End-User Customer’s acceptance of Products.

 

	 	4.3.	Invoices. Supplier shall submit an invoice to Company for all each order after its shipment. All invoices shall specify the purchase order to which it relates
and reference any discounts or rebates that may be applicable to such order. 

  

	 	4.4.	Payment Terms. Payments for each order shall be made in U.S. dollars net 45 days from the date a complete and accurate invoice for an applicable order is
received by Company. 

  

	5.	Rebates, Discounts, and Incentives. 

  

	 	5.1.	Any rebates, credits, incentives, or discount programs provide by Supplier to Company under this Agreement are specified on Exhibit B. The Parties acknowledge
that any price reductions or incentive remuneration provided under the terms of this Agreement constitute “discounts or other reductions in price” under section 1128 B(b)(3)(A) of the Social Security Act 42 U.S.C. 1320a-7b(b)(3)(A).
Accordingly, Company shall disclose any rebates or discounts to its Customers and require that its Customers for Product properly disclose this and any other “bonus, discount, rebate, or other reduction in price” provided to Company by
Supplier to any state or federal program that provides cost or charge-based reimbursement to such Customer for Product. 

  

	6.	Supplier’s Duties. 

  

	 	6.1.	Supplier shall ready goods for shipment, pack and deliver goods to Company’s designated carriers in accordance with Customer’s order and reasonable shipping
schedule.. 

  
 4 

			
	

	  	Master Supply and Distribution Agreement

  

	 	6.2.	Supplier shall ensure that all Products shall have a shelf life of at least 18 months at its time of delivery to Company or Company’s designee. Product with an
expiration date shall have an expiration date of 18 months or greater from the date of delivery to Company or Company’s designee. 

  

	 	6.3.	Supplier shall refrain from modifying the Products or the key components except if required by the FDA or other government agencies, including, (i) composition or
source of any raw material or components; (ii) method of producing or testing Product; (iii) change in subcontractors or suppliers for producing, obtaining, processing, or testing; and (iv) site of manufacture, unless it first
receives Company’s written consent for such modifications. 

  

	 	6.4.	If Company receives a material number of complaints from Company’s customer that relate to Products not performing to Company’s specifications or being
otherwise nonconforming, the Supplier is responsible to investigate and report the accuracy of the complaints. A material number of customer complaints, means a number of complaints equal to 6% or more of the rolling average of purchases of such
Products over the past two months. 

  

	 	6.5.	Supplier shall offer Company the right to be the exclusive distributor of any improvement to Product or any product that could be competitive to Product before offering
it to any other person or company for distribution. If Company accepts such improved or new product as its exclusive distributor, the terms of this Master Agreement shall apply, subject to Parties’ mutual agreement to the prices for such
improved or new product. 

  

	 	6.6.	Supplier shall maintain the Mandatory Fill Rate on all orders for Products. If Supplier fails to meet the Mandatory Fill Rate by the Delivery Date, Company may charge
and Supplier will pay Company a delinquency charge for each day that the Mandatory Fill Rate for the respective purchase order remains unsatisfied. The delinquency charges shall be determined on the basis of the following schedule based on a
standard lead time of 60 days for all products: 

  

			
	 Days Delinquent
	  	Daily Penalty
	
1st through 14th
day delinquent
	  	% 2
	
15th through 30th
day delinquent
	  	% 5
	
31st day and any day thereafter
	  	% 10

  

	 	6.7.	If due to a delay in Product delivery or nonconforming Product quality, Company deems it necessary to obtain substitute product from another supplier. To the extent the
acquirement of such substitute product, including freight costs, exceeds the price Company would have paid under the Agreement for timely delivered conforming Product, Supplier will pay Company an amount equal to the extra costs incurred by Company
to acquire such substitute product. 

  

	 	6.8.	Supplier shall obtain and maintain any governmental approvals, consents, licenses, authorizations, declarations, filings, and registrations as may be necessary or
advisable for the performance of the terms and conditions of this Agreement, including, without limitation, any approvals and licensing by the United States Food and Drug Administration (“FDA”) Drug Enforcement Administration
(“DEA”), and pharmaceutical boards, as applicable. 

  
 5 

			
	

	  	Master Supply and Distribution Agreement

  

	 	6.9.	Company shall be responsible for installation, user education and service, required with respect to Product sold by Company, including all related costs and expenses.

  

	 	6.10.	Supplier shall make available to Company at least once during the first 6-months and at least once during the second 6-months of each Contract Year, comprehensive
training to Company’s sales and customer service teams, at such time(s) and place(s) as are mutually agreed by the Parties to be convenient. All Supplier costs and expenses relating to such training, including but not limited to travel expenses
of Supplier’s employees and agents, but not the Company’s employees or agents, shall be borne by Supplier. 

  

	 	6.11.	Upon Company’s request, Supplier shall provide Company with (i) demo instruments to be used by Company’s sales personnel, at a thirty-five
(35) percent reduction in contract price and (ii) additional demo instruments, at Supplier’s cost, to be used in clinical studies and to produce white papers. No more than five (5) percent of the annual purchase order quantity
can be product samples. 

  

	 	6.12.	Supplier shall use its best efforts to provide a website link from Supplier’s website to Company’s website within 30-days after the Effective Date.

  

	 	6.13.	Supplier shall provide Material Safety Data sheets for potentially harmful substances provided to Company by Supplier, to the extent required by law.

  

	7.	Company’s Duties. 

  

	 	7.1.	Company shall use commercially reasonable efforts (i) to sell Products to appropriate institutions, (ii) to develop and maintain a qualified sales force for
promotion and sale of Products, (iii) to maintain sufficient inventory of Products to service the needs of its customers, (iv) to timely expedite shipping of Products in Company’s inventory to customers ordering Products, (v) to
comply in all material respects with all laws that relate to the importation, sale, or distribution of any Products in the Market, and (vi) to refrain from knowingly taking any action that it knows violates any laws, regulations, treaties, or
conventions that apply to its activities. 

  

	 	7.2.	Company shall collaborate with Supplier to develop joint marketing and branding plans for Products. 

 

	 	7.3.	Company shall use, market, sell, and distribute Products according to the Products specifications, instructions, packaging, and labeling provided to Company by Supplier
without alteration, modification, or tampering, unless consented to in writing by Supplier. 

  

	 	7.4.	Company shall maintain electronic records of each Product sold by Company and to whom it was sold for at least 3 years following the date of the sale of Product to its
customer. 

  
 6 

			
	

	  	Master Supply and Distribution Agreement

  

	 	7.5.	Company shall refrain from selling, marketing, or distributing Products outside the Territory. 

 

	 	7.6.	Upon Supplier’s request, Company shall provide Supplier with tracing reports at such frequency as the Parties shall mutually agree; provided, for the period
beginning on the date of the initial request reports until the termination of this Agreement. 

  

	8.	Warranty. 

  

	 	8.1.	In addition to any warranty included in manual or other documentation provided by Supplier with Product, all of which are incorporated herein by reference, Supplier
warrants that Products shall conform to the specifications contained in the Agreement and be free from defects in materials, workmanship, and design. Supplier warrants that it has title to the Products it sells to Company and that such Products will
be free and clear of all liens, claims, or encumbrances and will be patient-ready condition at the time of transfer to Company. Supplier further warrants that the Product delivered to Company under this agreement shall have been manufactured in
accordance with all applicable statues, ordinances and regulations, including, without limitation, U.S. Food, Drug & Cosmetic Act and the regulations promulgated there under (the “Act”), including the Good Manufacturing Practice
regulations that are now in force or herein after adopted (“Good Manufacturing Practices”) by the FDA. Supplier warrants that all expiration dates on Products are accurate. Supplier warrants that Products shall be properly branded and
unadulterated at the time of shipment from the Supplier’s facility, in accordance with all applicable laws. 

  

	 	8.2.	All warranties under this Agreement, including, but not limited to, any warranty included in a manual or other documentation provided with Product, shall remain in
effect for at least 12 months following the date of the Products delivery by Company to its customers or, if longer, the date specified in the manuals or other documentation provided by Supplier with Products. 

 

	9.	Shipping and Marking. 

  

	 	9.1.	Supplier shall mark and ship Products to Company in accordance with (i) all legal requirements for shipment of such Products, and (ii) the instructions set
forth in this Agreement and any purchase orders issued with respect hereto. Each shipment shall include paperwork specifying the purchase order and a description of the Products (including quantity) included in each shipment.

  

	 	9.2.	The receiving hours at Company’s locations shall be Monday through Friday 8 am to 3 pm in the time zone of delivery destination. In the event other shipping
arrangements are proposed, Supplier’s shipper or carrier must obtain prior approval from the receiving agent at the delivery location. No more than three trucks per day may be sent to Company for unloading, unless previously agreed between the
Parties. Company will not pay demurrage or any other charges for any trucks sent in excess of this number per day or for trucks that arrive too late to be unloaded. 

  
 7 

			
	

	  	Master Supply and Distribution Agreement

  

	 	9.3.	A complete Supplier’s “bill of material” or advance shipping notice containing all special handling, storage or lifting requirements, is required to be
delivered to Company’s carrier prior to shipment. This information should also be submitted to the receiving agent at Company’s designated location via fax or E-mail. 

 

	 	9.4.	Company shall inspect Products within 30 days of delivery for count and readily discernible non-conformities in the overall order, including, without limitation,
package condition, product codes, package labels, and expiration dates. Company shall notify Supplier of any non-conformity found in this initial inspection. Supplier shall have 30 days to correct the initial order by providing conforming
replacement Products, at no additional cost to Company. After the order is found to satisfy this initial inspection and all non-conformities, if any, have been remedied, Company will have 30 additional days to thoroughly inspect the Products.
Company shall notify Supplier of any non-conformity found in this initial inspection. Supplier shall have 30-days to correct the initial order by providing conforming replacement Products, at no additional cost to Company. Supplier shall reimburse
Company for the price (including any taxes and fees incurred for such order) of any Products remaining non-conforming after this second cure period. At the conclusion of this period, Products shall be deemed to be accepted by Company. Title and risk
of loss with respect to the Products shall pass to Company upon Company’s acceptance of Products. Supplier shall bear all risk of loss and shall insure all Products until acceptance by Company 

 

	 	9.5.	If after acceptance of Products in accordance with paragraph (a) above, Company determines that any Products fail to meet any of the warranties stated in
Section 9, Company will give Supplier notice of nonconforming Products and return such nonconforming Products to Supplier, and Supplier shall, at Supplier’s option and at Supplier’s expense: (i) replace within 30 days such
Products with new Products that comply with this Agreement and the Specifications (as hereinafter defined); or (ii) issue Company a refund or credit in the full amount of the price of the nonconforming units. 

 

	10.	Indemnification. 

  

	 	10.1.	Product Liability Indemnity. Supplier shall indemnify, defend, and hold all Company Parties harmless against all third-party any and all Claims arising out of,
or in connection with, (i) any breach of any representation, warranty, or covenant by Supplier hereunder, or (ii) any negligent or intentionally wrongful act or omission by Supplier in connection with the manufacture, packaging, or
labeling of any Products or in connection with any instructions or manuals provided for the Products. 

  

	 	10.2.	Indemnification by Company. Company shall indemnify, defend, and hold Supplier harmless against any and all Claims arising out of, or in connection with,
(i) any breach of any representation, warranty, or covenant by Company hereunder, or (ii) any negligent or intentionally wrongful act or omission by Company in connection with the sale or distribution of any Products to its customers.

  
 8 

			
	

	  	Master Supply and Distribution Agreement

  

	 	10.3.	Intellectual Property Indemnity. Supplier shall indemnify defend, and hold harmless all Company Parties from and against all Claims based on allegations
or claims (whether valid or invalid) that the Products, or the sale, offer for sale, or use thereof constitutes an infringement or violation of any patent, trademark, copyright, or proprietary information right. Company may participate at its own
expense in any defense of such Claim undertaken by Supplier. Without limitation of the foregoing, in the event of a Claim described in this paragraph (c), Supplier shall promptly as possible: 

 

	 	10.3.1.	Procure for Company the unrestricted right to continue using the Product for the term of this Agreement; 

 

	 	10.3.2.	Replace Products with non-infringing, non-violating, compatible products with specifications and performance equal to or better than the unmodified Products; or

  

	 	10.3.3.	Modify Products so they are no longer infringing or violating while maintaining compatibility, specifications, and performance equal to or better than the unmodified
Products. 

  

	 	10.3.4.	If, in the course of any Claim described under this paragraph c, Supplier, Company, or any customer of Company is enjoined or is sought to be enjoined from use of any
Product, or any method or operation performed by a Product, pending final resolution of such Claim, Supplier shall immediately post a bond in a form and in an amount sufficient to allow Supplier to continue its obligations to Company and to enable
Company and its customers to use the Products and all methods and operations performed by the Product, until the Claim is resolved. 

  

	 	10.4.	Limitation on Liability. EXCEPT TO THE EXTENT A PARTY HAS AN INDEMNIFICATION DUTY PURSUANT TO THIS SECTION 12, IN NO EVENT SHALL EITHER PARTY BE LIABLE
FOR SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

  

	11.	Insurance. Supplier will maintain commercial general liability and products liability insurance covering each occurrence of bodily injury and property damage in
an amount not less than $5,000,000 combined single limit with endorsement for blanket contractual and vendor’s liability. Supplier shall, on or before delivery of any Products hereunder, furnish to Company a certificate of insurance evidencing
the foregoing coverage and limits. At the same time, Supplier shall provide Company with a written statement from the insurer, either on the certificate or separately, stating that Company is named as an additional insured on the policy and that
insurer will give Company at least 30 days prior written notice of any cancellations, non-renewal, or material change in coverage. 

  

	12.	Quality and Regulatory. 

  

	 	12.1.	Quality Assurance. Supplier shall inspect each lot of Product to be supplied to Company in order to evaluate Products full conformity with all Supplier and
Company expectations for Product. Such evaluation should include, but not be limited to, evaluating (i) Products’ compliance with all relevant laws and regulations, (ii) Products’ conformity with all specifications of Agreement
and Purchase order, (iii) sufficient expiration periods for Products, and (iv) whether there have been any changes in Product materials, methods of producing or processing Product, or Product performance., processing, or testing; or
(v) change in subcontractors for producing or processing Product. As soon as possible after their discovery, Supplier shall notify Company in writing of any changes or deviations from expectations found in the evaluation.

  
 9 

			
	

	  	Master Supply and Distribution Agreement

  

	 	12.2.	Regulatory Deficiencies. Supplier agrees to perform, at no cost to Company, all corrective action needed to fix regulatory deficiencies in Products. In the event
of any corrective action or recall of Products by Supplier, Company will either notify its customers of such actions or advise them of the remedy to be provided by Supplier or provide Supplier a list of customers that have purchased said product for
Supplier to give such notice. Supplier will affect all such remedies by providing instructions to Company to provide to its customers for return of Product to Supplier for correction and/or modification. Supplier will be responsible for all costs
and expenses incurred in affecting such a remedy including costs of service, replacement, and shipping, as applicable. 

  

	 	12.3.	Product Complaints. In the event that either party receives any complaints regarding the Products, it shall promptly notify the other party of such. At
Company’s request, Supplier shall investigate and evaluate these complaints and communicating the results thereto to Company in writing within 10 business days of notification by the applicable party; provided that, if any such investigation
requires more than 10 business days to complete, Supplier shall so notify Company of such in writing within the aforesaid 10 business days. Supplier will make a preliminary evaluation of each complaint it receives and will conduct all follow-up,
communications and maintenance of records with respect to such complaints as required by applicable law and will cooperate with Company in the resolution of such product complaints. Supplier shall be responsible for making all necessary reports to
the FDA and/or any other applicable regulatory agency or authority and shall provide copies of such reports to Company and allow Company a reasonable opportunity to review and comment on any such reports prior to the filing of such reports with the
FDA so long as this permits timely filing with the FDA or other regulatory agency. 

  

	13.	Confidentiality. Each Party agrees at all times during the Term and for a period of 3 years thereafter to hold in strictest confidence, and not to use, except in
connection with the performance of obligations under this Agreement, and not to disclose to any person or entity (except for its Affiliates and those of its employees and contractors who have a “need to know” in connection with the
performance of obligations under this Agreement) without the prior written authorization of the Chief Executive Officer or President of the Disclosing Party, any Confidential Information of the Disclosing Party disclosed to the Receiving Party in
connection with this Agreement, either directly or indirectly in writing, orally or by drawing or inspection of documents or other tangible property. Further, each Party agrees at all times during the Term and for a period of 3 years thereafter to
not disclose the existence of this Agreement or any of the terms herein, without the written consent of the other Party, except as may be required by governing laws, including the rules and regulations of the Securities and Exchange Commission. The
confidentiality provisions herein shall supersede any prior confidential agreement between the parties. 

  
 10 

			
	

	  	Master Supply and Distribution Agreement

  

	14.	Bona Fide Offer. If Company receives an offer from another supplier to provide products substantially similar to the Products on terms and conditions, including
without limitation pricing, more favorable to Company than those in this Agreement, Company will provide Supplier with written notice of such offer (a “Notice of Offer”). Supplier will have 30 days following the date of the Notice of Offer
to notify Company that it agrees to meet or improve upon such offer. If Supplier fails to notify Company in writing that it will meet or improve upon such offer within such 30 day period, or if it notifies Company in writing within such period that
it will not meet such offer, Company may terminate this Agreement upon written notice to the Supplier. If within such 30 day period, Supplier notifies Company in writing that it agrees to meet or improve upon such offer, Supplier’s offer or
improvement will be deemed an amendment to this Agreement with respect to the Products on the terms and conditions set forth in such offer or improvement. 

  

	15.	Termination. Generally this Agreement shall terminate at the end of the Term or as otherwise provided hereinabove. In addition: 

 

	 	15.1.	Termination for Failure to Obtain 510K. Company shall have the right to terminate, resend or revoke this agreement at any time in the event the 510K for the
products is not approved by the FDA within 12 months of this agreement being executed. For purposes of this section, the Execution Date of this agreement shall be the date set forth on the signature page. 

 

	 	15.2.	Termination for Cause. Each Party reserves the right to terminate the Agreement if: (i) the other Party ceases to function as a going concern in the
normal course of business; (ii) the other Party commits or suffers any act of bankruptcy or insolvency; or (iii) to the extent another remedy is not provided under this Agreement, the other Party fails to cure any material breach in the
provisions of this Agreement within 30 days of after receipt of written notice of such breach been given by then non-breaching Party to the breaching Party. 

 

	 	15.3.	Termination upon Mutual Agreement. The Parties may terminate this Agreement upon mutual written agreement of the Parties. 

 

	 	15.4.	Consequence of Termination of Agreement. Upon the termination of the Agreement, the following provisions shall apply: 

 

	 	15.4.1.	Company may sell any Products that are in its possession or which are subsequently delivered pursuant to an outstanding Purchase order under this Agreement; provided
however, Supplier shall repurchase from Company all Products then owned by Company upon notice and request by Company, at prices equal to those at which Company purchased them from Supplier should Supplier terminate Company. If Company terminates
Supplier then Supplier will have the option to repurchase. Company shall submit to Supplier a list of Products subject to repurchase upon termination, within 30 days after receipt of notice of termination or the expiration of the Term or any renewal
term. Supplier will promptly pay Company for returned Products. 

  
 11 

			
	

	  	Master Supply and Distribution Agreement

  

	 	15.4.2.	Company will have the right to represent itself as an authorized distributor of Supplier until all of Company’s inventory of Products has either been returned for
credit by Supplier or has been sold by Company. As of the later of the date as of which (A) the expiration or termination of this Agreement occurs or (B) Company no longer has possession or control of any Products of Supplier, the rights
of Company shall immediately terminate and Company shall cease to identify itself as an authorized Company of Products and Company shall not use Supplier’s name on any products sold after such termination. The acceptance of any Purchase order
from or the sale of any Products to Company after the expiration or termination of this Agreement shall not be construed as a renewal or extension hereof, nor as a waiver of termination of this Agreement; however, the processes and obligations for
each such order shall be governed by provisions identical to the applicable provisions of this Agreement. 

  

	 	15.4.3.	After termination of the Agreement, Company shall have the ability to continue to purchase Product, for a period of not more than 90 days to the extent necessary for
Company to honor existing contractual relationships with customers at the Prices in effect at the date of termination of the Agreement. 

  

	 	15.4.4.	Each Party shall return or destroy any Confidential Information of the other Party in its possession as of any termination. 

 

	 	15.4.5.	If this Agreement is terminated by Supplier for any reason other than cause, during the initial Term, in addition to other remedies available to Company, Supplier will
reimburse Company its actual out-of-pocket direct expenses incurred training Company’s personnel, on any aspect of Supplier’s Products. 

  

	 	15.5.	Survival. Sections 8, 10, 11, 13, 15, and 20shall survive termination of this Agreement. 

 

	16.	Continuity of Supply. Supplier represents and warrants that it shall use best efforts to ensure that any subsequent owner or entity takes a controlling interest
in Supplier’s business, or any other successor or assignee to this Agreement, will agree to and comply with the terms of this Agreement as if it has fully assumed all obligations of Supplier hereunder. 

 

	17.	Relationship of Parties. Each Party is an independent contract of the other. Neither Party shall be the legal agent of the other for any purpose whatsoever ant
therefore has no right or authority to make or underwrite any promise, warranty, or representation, to execute any contract, or otherwise to assume any obligation or responsibility in the name of or on behalf of the other party, except to the extent
specifically authorized in writing by the other Party. Neither Party shall be bound by nor liable to any third party for the acts or obligations or debts incurred by the other toward such third party, except to the extent specifically agreed to in
writing by the party to be so bound. Further, for purposes of compliance with the FDA and all other laws and regulations relating to Products, Supplier is the manufacturer of the Products and shall comply with all obligations vested in the
manufacturer under such laws and regulations. 

  
 12 

			
	

	  	Master Supply and Distribution Agreement

  

	18.	Assignment. This Agreement and the rights and obligations hereunder shall be binding upon and inure to the benefit of the Parties hereto and their respective
successors and assigns; provided that no Assignment , sale or other assignment of this Agreement can occur unless either (i) the transfer occurs by way of merger, reorganization, consolidation, amalgamation, or as part of a transfer of all or
substantially all of the assigning party’s assets, or (ii) then non-transferring Party consents to the transfer. In the event of such a transfer, the transferring Party agrees to secure consent from the transferee that it will assume and
perform all obligations of the transferring Party under this Agreement. Supplier or Company shall give the other written notice of any anticipated assignment of the Agreement as soon as administratively practicable after such information may first
be made public. 

  

	19.	Force Majeure. Whenever performance by Supplier or Company of any of its obligations hereunder, is substantially prevented by reason of any act of God, strike,
lock-out, or other industrial or transportation disturbance, fire, law, regulation or ordinance, war or war conditions, or by reason of any other matter beyond its reasonable control, then such performance shall be excused, and deemed suspended
during the continuation of such event and for a reasonable time thereafter, delayed or adjusted accordingly. 

  

	20.	Publicity. No Party to this Agreement shall originate any publicity, news release or other public announcement, about, related to or arising out of this
Agreement, without the prior written consent of the other Party hereto if such other Party or any affiliate is named in such publicity, news release, or public announcement. A press release announcing this Agreement will be jointly developed and
released by the Parties. 

  

	21.	Non-solicitation. During the Term and for a period of 2 years thereafter, each Party agrees, on behalf of itself and its employees and representatives, not to,
directly or indirectly, employ, solicit for purposes of employment, offer to hire, entice away, or offer to enter into any contract with any director, officer or employee of the other Party, or otherwise solicit, induce or otherwise encourage any
such person to discontinue, cancel or refrain from entering into any relationship (contractual or otherwise) with the other Party without prior written consent of the such other Party. 

  
 13 

			
	

	  	Master Supply and Distribution Agreement

  

 Notices. 

 

	 	21.1.	All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by
personal delivery, registered or certified mail or overnight courier as provided herein), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, to the addresses first
specified hereinabove, or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith, to the attention of the Chief Executive Officer. In addition, a copy of any notice to
Company must be sent to General Counsel, Sarnova, Inc., 5000 Tuttle Crossing Boulevard, Dublin, Ohio 43016 (such copy shall not constitute legal notice) and a copy of any notice to Supplier must be sent to Morse, Zelnick, Rose & Lander, 405
Park Avenue, Suite 1401, New York, New York 10022, Attn: Stephen A. Zelnick, Esq. 

  

	 	21.2.	Any such communication shall be deemed to have been given (a) when delivered, if personally delivered or sent by facsimile on a business day, (b) on the
business day after dispatch, if sent by nationally-recognized overnight courier, and (c) on the third business day following the date of mailing, if sent by mail. It is understood and agreed that this Section 21 is not intended to govern
the day-to-day business communications necessary between the Parties in performing their duties, in due course, under the terms of this Agreement. 

  

	22.	Headings. The headings of this Agreement are for convenience only and shall not affect the meaning of the terms of this Agreement. 

 

	23.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Ohio, excluding any conflicts or choice of law rule
or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

  

	24.	Entire Agreement. The Parties hereto acknowledge that this Agreement, including the Appendices and documents incorporated by reference, sets forth the entire
agreement and understanding of the Parties hereto as to the subject matter hereof, and shall not be subject to any change of modification except by the execution of a written instrument subscribed to by the Parties hereto. This Agreement shall
supersede all previous communications, representations or understandings, either oral or written, between the Parties relating to the subject matter hereof. 

 

	25.	Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or
obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or
unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance
here from, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or
unenforceable provision as may be possible and reasonably acceptable to the Parties herein. To the fullest extent permitted by applicable law, each Party hereby waives any provision of law that would render any provision prohibited or unenforceable
in any respect. 

  
 14 

			
	

	  	Master Supply and Distribution Agreement

  

	26.	Waiver. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a
waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. 

  

	27.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 

 IN WITNESS WHEREOF, the parties hereto have executed this Company Agreement as of this 3rd day of
July, 2013 (“Execution Date”). 
  

							
	Milestone Scientific, Inc.	 	Tri-anim Health Services Inc.
				
	By:	  	  /s/ Leonard Osser
	 	By:	  	  /s/ Jeffrey Prestel

	Title:	  	President and CEO	 	Title:	  	President

  
 15 

			
	

	  	Master Supply and Distribution Agreement

  

 EXHIBIT A 
 PRODUCTS 
 Exclusive Products 

 

									
	 Product *
	  	Price	 	  	Private Labeled	 
	 Epidural Instrument
	  	$	3,500 each	  	  	 	N/A	  
	 Epidural disposable
	  	$	75.00 each	  	  	 	N/A	  

 Products denoted with a * may be private labeled. 

  
 16 

			
	

	  	Master Supply and Distribution Agreement

  

 EXHIBIT B 

 

	1.	GPO Rebate. With respect to each Contract Year, Supplier shall provide a rebate to Company equal to the amount of any fees paid by Company to members to which
Company sells Products. The terms of the rebate described under this Exhibit B Section 1 shall be set forth in a written rebate agreement executed by the Parties. 

 

	2.	GP Dollar Rebate. If there is a change in the price at which Product is sold to End-User Customers and/or to the Company and that change results in a decrease in
GP Dollars for such Product, Supplier will provide a quarterly rebate to Company equal to the amount of the decrease in GP Dollars incurred in the quarter with respect to which the quarterly rebate is provided. 

 

	3.	Rewards Rebate. In the event that certain Products, as identified on Exhibit C, are sold by Company to a customer participating in the Company’s
Tri-anim Rewards Program, Supplier shall pay Company a rebate in accordance with Exhibit C. 

  

	4.	Other Rebates, Discounts, or Incentives. Supplier may establish such additional rebate, credit, incentive, or discount programs as the Parties shall from time to
time desire. 

  

	5.	Compliance with Safe Harbor Requirements. The Parties acknowledge that any price reductions or incentive remuneration provided under the terms of this Agreement
constitute “discounts or other reductions in price” under section 1128 B(b)(3)(A) of the Social Security Act 42 U.S.C. 1320a-7b(b)(3)(A). Accordingly, Company shall disclose any rebates or discounts to its customers and require that its
customers for Products properly disclose this and any other “bonus, discount, rebate, or other reduction in price” provided to Company by Supplier to any state or federal program that provides cost or charge-based reimbursement to such
customer for Products. 

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]